Fig. 1


A
ANTI-RSVA
Novex
Tris glyc
14%
monoclonal anti-F.
1/1000
B
ANTI-RSVA
Novex
Tris glyc
14%
monoclonal anti-F.
1/1000

Fig. 2


A
ANTI-RSVA
Novex
Tris glyc
14%
monoclonal anti-M
1/200


B
ANTI-RSVA
Novex
Tris glyc
14%
monoclonal anti-M
1/200

Fig. 3


A
ANTI-RSVA
Novex
Tris glyc
14%
monoclonal anti-G
1/200


B
ANTI-RSVA
Novex
Tris glyc
14%
monoclonal anti-G
1/200

Fig. 4


A
ANTI-RSVA
Novex
Tris glyc
14%
monoclonal anti-N
1/200


B
ANTI-RSVA
Novex
Tris glyc
14%
monoclonal anti-N
1/200

Fig. 5



Fig. 6



Fig. 7



Fig. 8



Fig. 9



Fig. 10



Fig. 11



Fig. 12


50000
45000
40000
35000
30000
25000
20000
15000
10000
5000
0
EU/ml
A
B
C
D
E
F
G

Fig. 13


Neutralization titers
18000
16000
14000
12000
10000
8000
6000
4000
2000
0
A
B
C
D
E
F
G

Fig. 14


Ig
IgG1
IgG2a
70000
60000
50000
40000
30000
20000
10000
0
EU/ml
A
B
C
D
E
F
G

Fig. 15



Fig. 16


Neutralization Titers
3500
3000
2500
2000
1500
1000
500
0
A
B
C
D
E

Fig. 17


Pre
d 21 Post priming
d 21 Post I
d 14 Post II
25000
20000
15000
10000
5000
0
EU/ml
A
B
C
D
E
F
G
H
I
J

Fig. 18


d 21 Post priming (Pool) Pool
d 21 Post 1 (Pool) Pool
d 14 Post 2 (Average on individuals)
Neutralization titers
40000
35000
30000
25000
20000
15000
10000
5000
0
A
B
C
D
E
F
G
H
I
J